HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Earnest, F. Articles by Midthun, D. E. Search for Related Content PubMed PubMed Citation Articles by Earnest, F. Articles by Midthun, D. E.

Suspected Non–Small Cell Lung Cancer: Incidence of Occult Brain and Skeletal Metastases and Effectiveness of Imaging for Detection—Pilot Study¹

¹ From the Department of Diagnostic Radiology (F.E., G.M.M., P.H.L., L.A.F., S.J.S.), the Division of Pulmonary and Critical Care Medicine (J.H.R., D.E.M.), and the Section of Biostatistics (C.M.R.), Mayo Clinic, 200 First St SW, Rochester, MN 55905, and the Department of Diagnostic Radiology, Mayo Clinic, Jacksonville, Fla (O.L.B.). Supported in part by grants from the Mayo Foundation for Education and Research and from Bracco Diagnostics. Received November 24, 1997; revision requested February 6, 1998; final revision received August 21; accepted November 5. Address reprint requests to F.E.

PURPOSE: To estimate the incidence of occult metastases to the brain and skeleton in patients suspected of having non–small cell lung cancer (NSCLC) (stage higher than T1N0M0) with surgically resectable disease, to assess the accuracy of screening magnetic resonance (MR) imaging and radionuclide bone scanning for help in identifying occult metastases, and to determine the effectiveness of a high dose of MR contrast material.

MATERIALS AND METHODS: Twenty-nine patients suspected of having NSCLC localized to the lung or to the lung and regional nodes underwent preoperative MR imaging with contrast material enhancement and radionuclide bone scanning for detection of brain or skeletal metastases. Patients were followed up for 12 months to determine the incidence of clinical metastatic disease.

RESULTS: Eight (28%) patients had occult metastatic disease to the brain or skeleton. Brain metastases were identified on MR images in five of six patients. Bone metastases were identified on MR images in four of five patients and on bone scans in three of five patients. MR imaging was no more accurate than bone scanning for skeletal evaluation. A high dose of MR contrast material allowed detection of more metastases and of small lesions.

CONCLUSION: Contrast-enhanced MR imaging of the brain is indicated for the exclusion of brain metastases in patients with clinically operable known or possible NSCLC and a large (>3-cm) lung mass. Skeletal imaging may be indicated if an isolated brain metastasis is detected.

Index terms: Brain neoplasms, MR, 10.121411, 10.12143 • Brain neoplasms, secondary, 10.3396 • Lung neoplasms, staging, 60.321 • Spine, MR, 30.121411, 30.12143 • Spine, radionuclide studies, 30.12172 • Spine, secondary neoplasms, 30.3396

This article has been cited by other articles:

				Y. Ohno, H. Koyama, Y. Onishi, D. Takenaka, M. Nogami, T. Yoshikawa, S. Matsumoto, Y. Kotani, and K. Sugimura Non-Small Cell Lung Cancer: Whole-Body MR Examination for M-Stage Assessment--Utility for Whole-Body Diffusion-weighted Imaging Compared with Integrated FDG PET/CT Radiology, August 1, 2008; 248(2): 643 - 654. [Abstract] [Full Text] [PDF]

				G. A. Silvestri, M. K. Gould, M. L. Margolis, L. T. Tanoue, D. McCrory, E. Toloza, and F. Detterbeck Noninvasive Staging of Non-small Cell Lung Cancer: ACCP Evidenced-Based Clinical Practice Guidelines (2nd Edition) Chest, September 1, 2007; 132(3_suppl): 178S - 201S. [Abstract] [Full Text] [PDF]

				D. Lardinois, W. Weder, M. Roudas, G. K. von Schulthess, M. Tutic, H. Moch, R. A. Stahel, and H. C. Steinert Etiology of Solitary Extrapulmonary Positron Emission Tomography and Computed Tomography Findings in Patients With Lung Cancer J. Clin. Oncol., October 1, 2005; 23(28): 6846 - 6853. [Abstract] [Full Text] [PDF]

				S. Erturan, M. Yaman, G. Aydin, I. Uzel, B. Musellim, and K. Kaynak The Role of Whole-Body Bone Scanning and Clinical Factors in Detecting Bone Metastases in Patients With Non-small Cell Lung Cancer Chest, February 1, 2005; 127(2): 449 - 454. [Abstract] [Full Text] [PDF]

				R. E Benamore, J. J Entwisle, and M. D Peake Bone scanning in lung cancer: Evidence is not sufficient to justify routine bone scanning BMJ, July 24, 2004; 329(7459): 230 - 231. [Full Text]

				D. G. Pfister, D. H. Johnson, C. G. Azzoli, W. Sause, T. J. Smith, S. Baker Jr, J. Olak, D. Stover, J. R. Strawn, A. T. Turrisi, et al. American Society of Clinical Oncology Treatment of Unresectable Non-Small-Cell Lung Cancer Guideline: Update 2003 J. Clin. Oncol., January 15, 2004; 22(2): 330 - 353. [Full Text] [PDF]

				S. G. Spiro and J. C. Porter Lung Cancer--Where Are We Today?: Current Advances in Staging and Nonsurgical Treatment Am. J. Respir. Crit. Care Med., November 1, 2002; 166(9): 1166 - 1196. [Abstract] [Full Text] [PDF]

				British Thoracic Society, Society of Cardiothoracic Surgeons of Great Britai, and Ireland Working Party Guidelines on the selection of patients with lung cancer for surgery Thorax, February 1, 2001; 56(2): 89 - 108. [Full Text]